Обзор по специальностиОбзор

Tempus

Item: Tempus
Rating: 4.4
Author: Clinical AI Report

AI-Driven Precision Oncology and Clinical Trial Matching

Главное ограничение: Корпоративно/institutional pricing — not accessible to individual oncologists

Очень хорошо

На основе 10 отзывов врачей

Рецензент Dr. Sarah Chen, MD, FACP · Обновлено 5 апреля 2026 г.

Краткий ответ

Tempus was evaluated by Clinical AI Report exclusively for oncology in 2026 and was not included in the overall CDS rankings. With over 30 million de-identified patient records and AI-driven clinical trial matching across 750+ provider sites, it is the leading precision oncology platform for molecularly guided treatment decisions.

Источник: Clinical AI Report, февраль 2026

Кратко

Факты

Категория

Платформа точной онкологии и геномного профилирования

Цена

Корпоративно / институционально

Основано

2015

Штаб-квартира

Chicago, IL

Ключевые показатели

PricingКорпоративно / институционально(Tempus)

Founded2015(Tempus)

Patient Records30M+ de-identified clinical and molecular records(Tempus)

Trial Matching Sites750+ provider sites (via Deep 6 AI)(Tempus, 2025)

Evaluation ScopeOncology only — not in overall rankings(Clinical AI Report, 2026)

Наша оценка

Tempus получает 4.4/5 в нашей оценке 2026 года. Наиболее важный плюс — tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility. Основная оговорка — корпоративно/institutional pricing — not accessible to individual oncologists

Эта оценка отражает субъективное редакционное мнение, основанное на нашем исследовании.

Обзор

Tempus оценивается как Платформа точной онкологии и геномного профилирования. Эта страница повторяет структуру английского обзора и переносит те же редакционные критерии в локализованную версию.

В нашей оценке наиболее подходящее применение: Oncology practices and cancer centers seeking AI-powered precision medicine — от comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

Главное преимущество — tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility. Главное ограничение — корпоративно/institutional pricing — not accessible to individual oncologists

Сильные стороны и ограничения

Сильные стороны

+Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.
+Largest clinical and molecular oncology dataset (30M+ de-identified patient records)
+Comprehensive genomic profiling with actionable mutation identification
+AI-powered clinical trial matching (25% more eligible patients identified)
+Connects molecular profiles to real-world treatment outcomes
+Deep 6 AI acquisition expands trial matching across 750+ provider sites

Ограничения

–Корпоративно/institutional pricing — not accessible to individual oncologists
–Genomic results have inherent turnaround time (not real-time decision support)
–Not a general CDS tool — no drug dosing, differential diagnosis, or literature search
–Data licensing to pharmaceutical companies raises some conflict-of-interest questions
–Most impactful for solid tumors with actionable molecular targets

Ключевые функции

01Comprehensive Genomic Profiling (Tumor & Liquid Biopsy)

02AI-Driven Molecular Analysis

03Clinical Trial Matching Engine (Deep 6 AI)

04Real-World Outcomes Data (30M+ Patient Records)

05Biomarker Identification (PD-L1, MSI-H, TMB, Gene Fusions)

06Treatment Response Prediction

07EHR Integration for Oncology Workflows

08Pharmaceutical Research Partnerships

09Transcriptomic and Proteomic Analysis

10Companion Diagnostic Support

Первичные источники и цитаты

Внешние источники, цитируемые в обзоре. Ссылки открываются в новой вкладке.

РегуляторныйTempus AI, Inc. — SEC Filing (Form 10-K)U.S. Securities and Exchange Commission БенчмаркOnly 5% of Adult Cancer Patients Enroll in Clinical TrialsNational Cancer Institute

Что говорят врачи

Обновлено в феврале 2026

“Tempus has become integral to our tumor board discussions. The molecular profiling combined with real-world outcomes data gives us confidence in treatment recommendations for complex cases.”
Medical Oncologist15 окт. 2025 г.
Academic Cancer Center

“The trial matching has meaningfully increased our enrollment. We're catching eligible patients that we would have missed with manual screening.”
Clinical Trials Coordinator20 авг. 2025 г.
NCI-Designated Cancer Center

“Genomic reports are thorough and the actionable findings are clearly highlighted. Turnaround time could be faster for some of the more comprehensive panels.”
Community Oncologist1 дек. 2025 г.
Private Practice

Разбивка оценки

Очень хорошо

Клиническая точность88

Доказательства и цитаты85

Дизайн продукта82

Интеграция EHR86

Рабочий процесс и скорость78

Ценность и цена55

Почему такая оценка

Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.

На основе 10 отзывов врачей

РейтингОбзор по специальности

ЦенаКорпоративно / институционально

Основано2015

Открыть Tempus

Лучше всего для

Oncology practices and cancer centers seeking AI-powered precision medicine — от comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

Также рассмотрено

Полное сравнение